Drug intelligence / Profile preview

d-leucovorin

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Intravenous, Oral, Intramuscular
01

Overview

d-leucovorin is the (6R)-diastereoisomer of leucovorin (folinic acid), a reduced folate derivative. While leucovorin is typically administered as a racemic mixture of d- and l-isomers, only the l-isomer (levoleucovorin) is biologically active in the metabolic pathways that potentiate 5-fluorouracil or provide a source of reduced folates during methotrexate rescue. d-leucovorin is considered biologically inactive in these therapeutic contexts but is characterized by a significantly longer plasma half-life (approximately 7-9 hours compared to 30-60 minutes for the l-isomer). It competes with l-leucovorin for transport into cells via the reduced folate carrier (RFC1) and for renal clearance, which may lead to competitive inhibition of the active isomer's efficacy. Consequently, pure l-leucovorin formulations have been developed to avoid the potential interference caused by the d-isomer.

Other names
dextroleucovorin(6R)-leucovorin(6R)-5-formyltetrahydrofolate(6R)-folinic acid
02

Targets

FOLR1 (FRα)SLC46A1 (Proton-coupled folate transporter)RFC1 (Reduced folate carrier type 1)

Beyond the preview

Go deeper on d-leucovorin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on d-leucovorin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call